Skip to main content
ZBIO
NASDAQ Life Sciences

Zenas BioPharma 计划同时进行普通股和可转换票据的公开发行

feedReported by Dow Jones Newswires
Sentiment info
Negative
Importance info
8
Price
$21.72
Mkt Cap
$1.271B
52W Low
$6.11
52W High
$44.6
Market data snapshot near publication time

summarizeSummary

Zenas BioPharma 宣布拟进行 2032 年到期的可转换高级票据和普通股的同时公开发行。这次资本募集是在公司最近于 3 月 16 日提交的 10-K 报告之后进行的，该报告详细披露了重大损失和“持续经营”警告，尽管也确认了其领先候选药物 obexelimab 的阳性 3 期试验结果。这些发行对于确保公司持续经营和潜在的 obexelimab 商业化提供资金是一个至关重要的步骤。然而，普通股和可转换票据的同时发行可能会导致现有股东的股份大幅稀释，并增加公司的债务负担，通常会导致股票价格在短期内出现负面压力。交易者将密切关注这些发行的规模和定价，以评估其全部影响。

在该公告发布时，ZBIO的交易价格为$21.72，交易所为NASDAQ，所属行业为Life Sciences，市值约为$12.7亿。 52周交易区间为$6.11至$44.60。 这则新闻被评估为消极市场情绪，重要性评分为8/10。 来源：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed ZBIO - Latest Insights

ZBIO
Apr 02, 2026, 5:44 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Key Insider Increases Stake Following Recent Public Offering
Sentiment: Positive
View Wiseek Article
ZBIO
Apr 01, 2026, 4:30 PM EDT
Filing Type: 4
Importance Score:
8
Director-Affiliated Fund Invests $3M in Zenas BioPharma Following Recent Public Offering
Sentiment: Positive
View Wiseek Article
ZBIO
Mar 31, 2026, 5:00 PM EDT
Filing Type: 4
Importance Score:
7
Director Lu Hongbo Buys $1.5M in Zenas BioPharma Public Offering, Signaling Confidence
Sentiment: Positive
View Wiseek Article
ZBIO
Mar 31, 2026, 4:35 PM EDT
Filing Type: 8-K
Importance Score:
8
Zenas BioPharma Closes $287.4M Concurrent Offerings to Fund Drug Launch and Pipeline
Sentiment: Neutral
View Wiseek Article
ZBIO
Mar 30, 2026, 9:20 AM EDT
Filing Type: 424B5
Importance Score:
8
Zenas BioPharma Prices Concurrent $200M Convertible Notes and $100M Equity Offerings
Sentiment: Negative
View Wiseek Article
ZBIO
Mar 30, 2026, 9:18 AM EDT
Filing Type: 424B5
Importance Score:
8
Zenas BioPharma Prices $100M Common Stock Offering at $20.00, Concurrent with $200M Convertible Notes
Sentiment: Negative
View Wiseek Article
ZBIO
Mar 27, 2026, 12:03 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Zenas BioPharma Shares Plunge 19% as $287.5M Dilutive Convertible Note and Stock Offerings Are Priced
Sentiment: Negative
View Wiseek Article
ZBIO
Mar 27, 2026, 6:04 AM EDT
Filing Type: FWP
Importance Score:
8
Zenas BioPharma Prices $300M Concurrent Offerings to Fund Commercial Launch and Pipeline
Sentiment: Positive
View Wiseek Article
ZBIO
Mar 27, 2026, 6:00 AM EDT
Filing Type: FWP
Importance Score:
8
Zenas BioPharma Prices $300M Concurrent Offerings to Fund Drug Launch and Extend Runway
Sentiment: Neutral
View Wiseek Article
ZBIO
Mar 27, 2026, 12:12 AM EDT
Source: GlobeNewswire
Importance Score:
8
Zenas BioPharma Prices $300M Concurrent Offering to Fund Drug Launch and Pipeline
Sentiment: Neutral
View Wiseek Article